Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Greg Lucier, Gail Page, and more

Greg Lucier 

Greg Lucier has become CEO of NuVasive, a medical device company focusing on spine surgery, after serving as the firm's interim CEO since April. He has been a member of NuVasive's board of directors since late 2013 and will continue as the board's chairman.

Until early 2014, Lucier was chairman and CEO of Life Technologies, which was acquired by Thermo Fisher Scientific last year. Previously, he was a corporate officer of General Electric and an executive at GE Medical Systems. Lucier holds a bachelor's degree in engineering from Pennsylvania State University and an MBA from Harvard Business School. 

Gail Page

Former Vemillion President and CEO Gail Page has joined NX Prenatal's board as executive chairperson to help guide the molecular diagnostic firm's commercial development of blood-based tests to support improved pregnancy outcomes. Page was president, CEO, and a director at Vermillion from 2006 to 2012. Prior to that, she was on the executive management team at Laboratory Corporation of America and at Luminex. In 2013, she founded Vineyard Investment Advisors. 

Patrick Hall, Robert Cook 

Castle Biosciences has appointed Patrick Hall as executive director of medical affairs, and promoted Robert Cook to executive director of research and development. Both are newly created positions. 

Hall, who will oversee Castle Bio's medical affairs strategies and programs, has 27 years of experience in the industry, including 11 years at Genomic Health, most recently as director of genomic science liaisons. Prior to that, he was medical science liaison at Genentech. 

Cook's was previously senior scientist at Castle Bio, which he joined in 2011. He has a Ph.D. from Northwestern University in biochemistry, molecular and cellular biology and did a post-doctoral fellowship at Baylor College of Medicine. Prior to his doctoral degree, he was at Gen-Probe, now part of Hologic.

Donald "Skip" Trump

Donald "Skip" Trump has been named CEO and executive director of the Inova Dwight and Martha Schar Cancer Institute.

Prior to coming to Inova, Trump was CEO and president of Roswell Park Cancer Institute in Buffalo, New York from 2007 to 2014.  

For more recent items on executive appointments and promotions in the omics and molecular diagnostics industries, please see the People in the News page on our website.

The Scan

Machine Learning Helps ID Molecular Mechanisms of Pancreatic Islet Beta Cell Subtypes in Type 2 Diabetes

The approach helps overcome limitations of previous studies that had investigated the molecular mechanisms of pancreatic islet beta cells, the authors write in their Nature Genetics paper.

Culture-Based Methods, Shotgun Sequencing Reveal Transmission of Bifidobacterium Strains From Mothers to Infants

In a Nature Communications study, culture-based approaches along with shotgun sequencing give a better picture of the microbial strains transmitted from mothers to infants.

Microbial Communities Can Help Trees Adapt to Changing Climates

Tree seedlings that were inoculated with microbes from dry, warm, or cold sites could better survive drought, heat, and cold stress, according to a study in Science.

A Combination of Genetics and Environment Causes Cleft Lip

In a study published in Nature Communications, researchers investigate what combination of genetic and environmental factors come into play to cause cleft lip/palate.